ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
15 avr. 2019 10h30 HE
|
Schall Law
LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc....
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX) and Encourages ZGNX Investors to Contact the Firm
12 avr. 2019 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California...
Bragar Eagel & Squire, P.C. is Investigating Zogenix, Inc. (ZGNX) on Behalf of Stockholders and Encourages ZGNX Investors to Contact the Firm
10 avr. 2019 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Zogenix, Inc. (NASDAQ: ZGNX). Our investigation concerns whether Zogenix has...
Zogenix Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
10 avr. 2019 11h30 HE
|
Block & Leviton LLP
BOSTON, April 10, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Zogenix, Inc....
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
09 août 2016 16h01 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
21 juin 2016 08h00 HE
|
Zogenix, Inc.
- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
05 mai 2016 08h00 HE
|
Zogenix, Inc.
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
19 janv. 2016 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...